^
Association details:
| Biomarker: | BRCA2 mutation + ER positive + PGR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Single center experience with Abemaciclib Administration in unfavourable relapsed breast cancer patients with progression after Palbociclib
Published date:
09/04/2020
Excerpt:
During the period from October 2019 to July 2020, 13 patients with recurrent advanced breast cancer received therapy with Abemaciclib…BRCAm 1 positive patients were 1, all were HER2 negative and ER/PR positive...substantial increase in subsequent rates of disease-free survival, even in highly unfavourable cases.
